benzinga.com
Negativewww.benzinga.com ·
nrx pharmaceuticals earnings are imminent these most accurate analysts revise
TRIALTAX_FNCACT_ANALYSTEPU_CATS_HEALTHCARETAX_DISEASE_DEPRESSION
Topic context
This topic has been covered 241611 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article covers NRx Pharmaceuticals' upcoming earnings and FDA clearance for a clinical trial. The commercial mechanism is weak: no concrete revenue or cost impact from the trial yet, and earnings are estimates. The primary sector is PHARMA_BIOTECH, but no strong supply chain or margin channel is triggered.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- NRx Pharmaceuticals to report Q1 earnings on May 18, expected loss of $0.11/share vs -$0.34 YoY
- Expected quarterly revenue $19.43 million
- FDA clearance received on May 7 to begin clinical trial of NRX-101 for depression and suicidality
- Stock rose 8.8% to $3.21 after FDA news
